Y-mAbs Reports EMA's Acceptance of Pediatric Investigation Plan for Omburtamab
Shots:
- EMA has agreed to the Y-mAbs’ proposed Pediatric Investigation Plan (“PIP”) for Omburtamab which follows EMA’s Pediatric Committee’s positive opinion
- The PIP approval allows Y-mAbs to file MAA of Omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastases from neuroblastoma with its anticipated submission in H2’20
- Omburtamab is mAb targeting B7-H3- being developed by Y-mAbs to treat CNS/leptomeningeal metastases from neuroblastoma- indication targeted by the PIP + number of additional cancer indications
Click here to read full press release/ article | Ref: Y-mAbs | Image: Y-mAbs
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com